Cytoreductive nephrectomy became accepted as standard of care for selected patients with
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …

Substantial improvement in prognosis among metastatic renal cell carcinoma (mRCC)
patients has been achieved, owing to the rapid development and utilization of …

Background In clear cell renal cell carcinoma (ccRCC), first-line treatment combines
nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with …

Renal cell carcinoma (RCC) is the most common renal malignancy with a rapidly increasing
morbidity and mortality rate gradually. RCC has a high mortality rate and an extremely poor …

Since their initial description by Elie Metchnikoff, phagocytes have sparked interest in a
variety of biologic disciplines. These important cells perform central functions in tissue repair …

Simple Summary The identification of clinical and tumor factors to identify patients who most
benefit from oncological treatments is a crucial clinical unmet need. We studied differences …

Kidney cancer is one the most lethal cancers of the urinary system, but current treatments
are limited and its prognosis is poor. This study focused on kidney renal clear cell carcinoma …

Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic
renal cell carcinoma (mRCC). Although many studies have reported biomarkers as …

Clear cell renal cell carcinoma (ccRCC) is associated with complex immune interactions. We
conducted a comprehensive analysis of immune-related differentially expressed genes in …

Nivolumab and ipilimumab (NIVO+ IPI) is standard therapy for patients with advanced renal
cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in …